Articles by Yousef Zakharia, MD
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.